Celgene Corporation (CELG)
Symbol Info
Listed Symbol CELG
Name Celgene Corporation
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $15,265,000,000
Latest Fiscal EPS $5.52
Price Info
21 Day Moving Average $99.6919
21 Day EMA $99.882530
50 Day Moving Average $97.8418
50 Day EMA $98.154430
200 Day EMA $93.640390
200 Day Moving Average 93.192050
52 Week High $103.08
52 Week Low $58.59
52 Week Change $24.110899
Alpha -0.005794
Beta 1.3984
Standard Deviation 0.099110
R2 0.234777
Periods 60
Share Information
10 Day Average Volume 3,368,652
20 Day Average Volume 3,683,833
30 Day Average Volume 3,565,119
50 Day Average Volume 3,400,153
Outstanding Shares 708,741,260
Float Shares 704,904,585
Percent Float 99.46%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 2,589
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 65,873,820
Institute Holdings Percent 98.300000
Institute Sold Previous 3 Months 113,170,813
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 37
Insider Holdings Percent 0.50%
Insider Sold Previous 3 Months -
Insiders Shares Owned 3,836,675
Price Change
7 Day Price Change $2.3799973
7 Day Percent Change 2.37%
21 Day Price Change $4.0999985
21 Day Percent Change 4.15%
30 Day Price Change $4.2799990
30 Day Percent Change 4.34%
Month To Date Price Change $3.6500
Month To Date Percent 3.68%
90 Day Price Change $12.039993
90 Day Percent Change 13.24%
Quarter To Date $3.649994
Quarter To Date Percent 3.68%
180 Day Price Change $9.189995
180 Day Percent Change 9.80%
200 Day Price Change $9.250000
200 Day Percent Change 9.87%
Year To Date $38.860000
Year To Date Percent 60.63%
Profile
Description Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Details
Issue Type CS
Market Cap $72,964,912,717
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 708,741,260
CEO Mark J. Alles
Employees 8,852
Last Audit UE
Classification
CIK 0000816284
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 86 Morris Avenue
Summit, NJ 7901
Website http://www.celgene.com
Facisimile
Telephone +1 908 673-9000
Email ir@celgene.com
Key Ratios
Profitability
EBIT Margin 42.20
EBITDA Margin 46.2
Pre-Tax Profit Margin 27.6
Profit Margin Cont 33.62
Gross Margin 96.20
Profit Margin TOT 33.62
Income Statements
Revenue $12,459,000,000
Revenue Per Share $17.5791
Revenue 3 Years $7.95
Revenue 5 Years $14.47
Valuation Measures
PE Ratio 13.40
Enterprise Value $80,845,007,118
Price To Sales 5.856402
Price To Free Cash 12.400000
PE High Last 5 Years 70.9
Price To Book 6.9
Price To Cash Flow 8.9
PE Low Last 5 Years 16.1
Price To Tangible Book -5
Financial Strength
Total Debt To Equity 2.0
Int Coverage 9.0
Current Ratio 3.4
Leverage Ratio 4.0
Quick Ratio 3.2
Long Term Debt To Capital 0.66
Assets
Receivables Turnover 2.3
Invoice Turnover 0.90
Assets Turnover 0.10
Management Effectiveness
Return Assets 14.52
Return On Equity 78.20
Return On Capital 22.06
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
CELG
Celgene
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.